The heterogeneity in clinical background (idiopathic TTP vs. disease-associated TMA, including TA-TMA) and plasma concentration of markers (normal vs. decreased ADAMTS13 activity) is well emphasized and represents a barrier to the development of clear treatment guidelines. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.